Bempedoic acid

Last updated

Bempedoic acid
Bempedoic acid.svg
Clinical data
Trade names Nexletol, Nilemdo
Other namesESP-55016, ETC-1002
AHFS/Drugs.com Monograph
MedlinePlus a620020
License data
Pregnancy
category
  • Contraindicated
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding 99.3% [2]
Metabolism Glucuronidation
Elimination half-life 21±11 hrs
Excretion 70% urine, 30% feces
Identifiers
  • 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.238.679 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C19H36O5
Molar mass 344.492 g·mol−1
3D model (JSmol)
  • CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O
  • InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)
  • Key:HYHMLYSLQUKXKP-UHFFFAOYSA-N

Bempedoic acid, sold under the brand name Nexletol among others, is a medication for the treatment of hypercholesterolemia (high blood cholesterol levels). [2] [3]

Contents

The most common side effects include hyperuricemia (high blood levels of uric acid), pain in arms or legs, and anemia (low red blood cell counts). [3]

Bempedoic acid blocks an enzyme in the liver called adenosine triphosphate-citrate lyase, which is involved in making cholesterol. [3]

Bempedoic acid was approved for use in the United States in February 2020, and for use in the European Union in April 2020. [3] [5] [6] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7]

Medical uses

In the US, bempedoic acid is indicated for the treatment of hypercholesterolemia in combination with diet and the highest tolerated statin therapy in adults with heterozygous familial hypercholesterolemia, or with established atherosclerotic cardiovascular disease, who need additional lowering of LDL cholesterol. [2]

In the EU, bempedoic acid is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin; or alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, [8] or for whom a statin is contraindicated. [3]

Side effects

Common adverse effects in clinical trials were muscle spasms (3.6% of treated patients, as compared to 2.3% under placebo), pain in the back (3.3% versus 2.2%) or in a limb (3.0% versus 1.7%), gout (1.5% versus 0.4%), and gastrointestinal problems such as diarrhea. A less common but more serious adverse effect was tendon rupture in the rotator cuff of the shoulder, the biceps tendon or the Achilles tendon (0.5% versus 0.0%). [2]

Interactions

Bempedoic acid does not interact with the cytochrome P450 enzyme system in the liver and only weakly inhibits the transporter proteins SLCO1B1, SLCO1B3 and SLC22A7 (the latter possibly being responsible for the increase of uric acid in the blood, and therefore the adverse effect gout). Despite this, the drug increases blood levels of statins. The effect is most pronounced with simvastatin and pravastatin, whose AUC is increased about twofold. No other clinically relevant interactions have been found in studies. [2]

Pharmacology

Mechanism of action

Bempedoyl-CoA, the active metabolite. Coenzyme A is shown in blue. Bempedoyl-CoA.svg
Bempedoyl-CoA, the active metabolite. Coenzyme A is shown in blue.

Bempedoic acid is a prodrug. It is activated to the thioester with coenzyme A by the enzyme SLC27A2 in the liver. [9] The activated substance inhibits ATP citrate lyase, which is involved in the liver's biosynthesis of cholesterol upstream of HMG-CoA reductase, the enzyme that is blocked by statins. [10] [11]

The substance also activates AMP-activated protein kinase, but this effect is likely not relevant in humans. [9]

Pharmacokinetics

ESP15228, the (also) active metabolite ESP15228 skeletal.svg
ESP15228, the (also) active metabolite

Following oral intake, bempedoic acid reaches highest blood plasma concentrations after 3.5 hours. [2] Food does not affect its absorption. [2] When in the bloodstream, 99.3% of the substance are bound to plasma proteins. [2] About a fifth of the substance is reversibly converted by an aldo-keto reductase enzyme to a metabolite (called ESP15228) that is also pharmacologically active in form of its coenzyme A–thioester. [2] Of ESP15228, 99.2% are bound to plasma proteins. [2] Both bempedoic acid and the metabolite are inactivated by glucuronidation of their carboxylic acid groups. [2]

Bempedoic acid has a biological half-life of 21±11 hours. [2] Over 95% of the substance are excreted in form of metabolites; about 70% with the urine and 30% with the feces. [2]

History

There were two clinical trials that evaluated the benefits and side effects of bempedoic acid. [6] The trial designs were similar. [6] All enrolled subjects were on a lipid-lowering diet and taking the highest dose of a statin (drug commonly used to lower cholesterol) for high cholesterol. [6] In both trials, subjects were randomly assigned to receive bempedoic acid or placebo tablets every day for 52-weeks. [6] Neither the subjects nor the health care providers knew which treatment was being given. [6] The trials measured percent change in LDL cholesterol (LDL-C) blood levels from baseline to week twelve and compared bempedoic acid to placebo. [6] In one clinical trial, bempedoic acid reduced LDL-C by about 20 mg/dl compared to placebo and had a similar frequency of side effects to placebo, although a higher percentage of drug-receiving subjects dropped out of the study because of side effects (11% vs. 7% under placebo). [10] In one randomized controlled trial, patients who could not tolerate therapy with statins had a reduced risk of major adverse cardiovascular events after being treated with bempedoic acid. [12]

In January 2020, the Committee for Medicinal Products for Human Use (CHMP) in the European Union recommended granting of a marketing authorization for bempedoic acid as both a standalone drug (brand name Nilemdo) [13] and as a fixed-dose combination medication with ezetimibe (brand name Nustendi). [14] Bempedoic acid was approved for use in the European Union in April 2020, [3] and the combination bempedoic acid/ezetimibe was approved in March 2020. [15] [16]

In February 2020, bempedoic acid was approved for use in the United States both as a standalone drug (brand name Nexletol) [5] [17] [18] [19] and in a fixed-dose combination with ezetimibe (brand name Nexlizet). [20] The U.S. Food and Drug Administration (FDA) granted the approval of Nexletol to Esperion Therapeutics. [2] [5]

The FDA approved bempedoic acid based on evidence from two clinical trials (Trial 1/ NCT02666664 and Trial 2/NCT02991118) of 3009 subjects with high LDL cholesterol and known atherosclerotic cardiovascular disease or HeFH. [6] The trials were conducted in United States, Canada, and Europe. [6]

See also

Related Research Articles

<span class="mw-page-title-main">Statin</span> Class of drugs used to lower cholesterol levels

Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering medications that reduce illness and mortality in those who are at high risk of cardiovascular disease. They are the most commonly prescribed cholesterol-lowering drugs.

Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.

<span class="mw-page-title-main">Fibrate</span> Class of chemical compounds

In pharmacology, the fibrates are a class of amphipathic carboxylic acids and esters. They are derivatives of fibric acid. They are used for a range of metabolic disorders, mainly hypercholesterolemia, and are therefore hypolipidemic agents.

<span class="mw-page-title-main">Atorvastatin</span> Cholesterol-lowering medication

Atorvastatin, sold under the brand name Lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. For the prevention of cardiovascular disease, statins are a first-line treatment. It is taken by mouth.

<span class="mw-page-title-main">Simvastatin</span> Lipid-lowering medication

Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. It is used along with exercise, diet, and weight loss to decrease elevated lipid levels. It is also used to decrease the risk of heart problems in those at high risk. It is taken by mouth.

<span class="mw-page-title-main">Fluvastatin</span> Chemical compound

Fluvastatin is a member of the statin drug class, used to treat hypercholesterolemia and to prevent cardiovascular disease.

<span class="mw-page-title-main">Pravastatin</span> Cholesterol lowering medication in the statin class

Pravastatin, sold under the brand name Pravachol among others, is a statin medication, used for preventing cardiovascular disease in those at high risk and treating abnormal lipids. It is suggested to be used together with diet changes, exercise, and weight loss. It is taken by mouth.

<span class="mw-page-title-main">Ezetimibe</span> Medication used to treat high cholesterol

Ezetimibe is a medication used to treat high blood cholesterol and certain other lipid abnormalities. Generally it is used together with dietary changes and a statin. Alone, it is less preferred than a statin. It is taken by mouth. It is also available in the fixed combinations ezetimibe/simvastatin, ezetimibe/atorvastatin, ezetimibe/rosuvastatin, and ezetimibe/bempedoic acid.

<span class="mw-page-title-main">Ezetimibe/simvastatin</span> Drug combination used for the treatment of dyslipidemia

Ezetimibe/simvastatin is a drug combination used for the treatment of dyslipidemia. It is a combination of ezetimibe and the statin drug simvastatin.

<span class="mw-page-title-main">Pitavastatin</span> Chemical compound

Pitavastatin is a member of the blood cholesterol lowering medication class of statins.

<span class="mw-page-title-main">Colesevelam</span> Pharmaceutical drug

Colesevelam is a bile acid sequestrant administered orally. It was developed by GelTex Pharmaceuticals and later acquired by Genzyme. It is marketed in the U.S. by Daiichi Sankyo under the brand name Welchol and elsewhere by Genzyme as Cholestagel. In Canada, it is marketed by Valeant as Lodalis.

<span class="mw-page-title-main">PCSK9</span> Mammalian protein found in humans

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. It is the 9th member of the proprotein convertase family of proteins that activate other proteins. Similar genes (orthologs) are found across many species. As with many proteins, PCSK9 is inactive when first synthesized, because a section of peptide chains blocks their activity; proprotein convertases remove that section to activate the enzyme. The PCSK9 gene also contains one of 27 loci associated with increased risk of coronary artery disease.

Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.

Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Ezetimibe/atorvastatin is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. It has also been approved to reduce elevated total cholesterol and elevated LDL in patients diagnosed with homozygous familial hypercholesterolemia as an adjunctive treatment to other hyperlipidemia treatments.

Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).

Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9.

Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. It is a combination of bempedoic acid and ezetimibe.

Fenofibrate/pravastatin, sold under the brand name Pravafenix, is a combination medication for the treatment of hypercholesterolemia in adults whose low-density lipoprotein (LDL) cholesterol is already being controlled with pravastatin alone but who still need to improve their cholesterol levels and to reduce their levels of triglycerides. It contains fenofibrate and pravastatin. It is taken by mouth.

Bempedoic acid/ezetimibe/atorvastatin is a combination therapy composed of bempedoic acid, ezetimibe, and atorvastatin. In a randomized study it showed a LDL-C reduction of 63.6 percent, significantly more than bempedoic acid/ezetimibe, and it may also be more effective than bempedoic acid / statin combination therapy.

References

  1. ↑ "Nilemdo 180mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 4 September 2020. Retrieved 17 January 2021.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Nexletol- bempedoic acid tablet, film coated". DailyMed. U.S. National Library of Medicine. 10 March 2020. Retrieved 19 March 2020.
  3. 1 2 3 4 5 6 7 "Nilemdo EPAR". European Medicines Agency (EMA). 29 January 2020. Retrieved 24 April 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ↑ "Nilemdo Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  5. 1 2 3 "Drug Approval Package: Nexletol". U.S. Food and Drug Administration (FDA). 24 March 2020. Retrieved 17 January 2021.
  6. 1 2 3 4 5 6 7 8 9 "Drug Trials Snapshots: Nexletol". U.S. Food and Drug Administration. 21 February 2020. Retrieved 27 March 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  7. ↑ "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021.
  8. ↑ Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJ, et al. (April 2023). "Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients". The New England Journal of Medicine. 388 (15): 1353–1364. doi:10.1056/NEJMoa2215024. hdl: 10044/1/103990 . PMID   36876740. S2CID   257362065.
  9. 1 2 Bilen O, Ballantyne CM (October 2016). "Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase". Current Atherosclerosis Reports. 18 (10): 61. doi:10.1007/s11883-016-0611-4. PMC   5035316 . PMID   27663902.
  10. 1 2 Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. (CLEAR Harmony Trial) (March 2019). "Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol". The New England Journal of Medicine. 380 (11): 1022–1032. doi: 10.1056/NEJMoa1803917 . hdl: 10044/1/68213 . PMID   30865796.
  11. ↑ "Bempedoic Acid". Esperion Therapeutics. Archived from the original on 20 June 2019. Retrieved 15 March 2019.
  12. ↑ Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJ, et al. (April 2023). "Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients". The New England Journal of Medicine. 388 (15): 1353–1364. doi:10.1056/NEJMoa2215024. hdl: 10044/1/103990 . PMID   36876740. S2CID   257362065.
  13. ↑ "Nilemdo: Pending EC decision". European Medicines Agency (EMA). 30 January 2020. Archived from the original on 31 January 2020. Retrieved 21 February 2020.
  14. ↑ "Nustendi: Pending EC decision". European Medicines Agency (EMA). 30 January 2020. Archived from the original on 31 January 2020. Retrieved 21 February 2020.
  15. ↑ "Nustendi EPAR". European Medicines Agency (EMA). 29 January 2020. Retrieved 17 January 2021.
  16. ↑ "Nustendi Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  17. ↑ "Esperion Announces FDA Approval of Nexletol (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine". Esperion Therapeutics, Inc. (Press release). 21 February 2020. Retrieved 21 February 2020.
  18. ↑ "FDA Approves Drug That Lowers Cholesterol in a New Way". The New York Times . Associated Press. 21 February 2020. Retrieved 21 February 2020.
  19. ↑ McGinley L (21 February 2020). "FDA approves first non-statin pill to treat high cholesterol in almost two decades". The Washington Post . Retrieved 21 February 2020.
  20. ↑ "Drug Approval Package: NEXLIZET". U.S. Food and Drug Administration (FDA). 17 April 2020. Retrieved 10 July 2021.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.